BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32113049)

  • 1. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
    Chen T; Zhuo LS; Liu PF; Fang WR; Li YM; Huang W
    Eur J Med Chem; 2020 Apr; 192():112174. PubMed ID: 32113049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development.
    Zhuo LS; Xu HC; Wang MS; Zhao XE; Ming ZH; Zhu XL; Huang W; Yang GF
    Eur J Med Chem; 2019 Sep; 178():705-714. PubMed ID: 31229873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X; Li HJ; Fang SB; Li QY; Wu YC
    Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
    Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
    Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
    Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
    Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold.
    Wang MS; Zhuo LS; Yang FP; Wang WJ; Huang W; Yang GF
    Eur J Med Chem; 2020 Jan; 185():111803. PubMed ID: 31677447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
    Zhang QW; Ye ZD; Shen C; Tie HX; Wang L; Shi L
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):124-133. PubMed ID: 30422010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
    Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
    Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
    Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
    J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and structure-activity relationships of novel 6,7-disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents.
    Tang Q; Zhao Y; Du X; Chong L; Gong P; Guo C
    Eur J Med Chem; 2013 Nov; 69():77-89. PubMed ID: 24012712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
    Liu Z; Wang R; Guo R; Hu J; Li R; Zhao Y; Gong P
    Bioorg Med Chem; 2014 Jul; 22(14):3642-53. PubMed ID: 24882675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
    Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
    Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene)pyrimidine-2,4,6-trione moiety as c-Met kinase inhibitors.
    Tang Q; Zhang G; Du X; Zhu W; Li R; Lin H; Li P; Cheng M; Gong P; Zhao Y
    Bioorg Med Chem; 2014 Feb; 22(4):1236-49. PubMed ID: 24485123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of Novel 4-Phenoxyquinolines Bearing 3-Hydrosulfonylacrylamido or 1H-Imidazole-4-carboxamido Scaffolds as c-Met Kinase Inhibitors.
    Wang J; Xie L; Wang Y; Wang X; Xi S; Zeng T; Gong P; Zhai X
    Arch Pharm (Weinheim); 2017 Feb; 350(2):. PubMed ID: 28133784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives bearing an imidazolone moiety as c-Met kinase inhibitors.
    Liao W; Hu G; Guo Z; Sun D; Zhang L; Bu Y; Li Y; Liu Y; Gong P
    Bioorg Med Chem; 2015 Aug; 23(15):4410-4422. PubMed ID: 26169763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and antiproliferative activity of 6,7-disubstituted-4-phenoxyquinoline derivatives bearing the 2-oxo-4-chloro-1,2-dihydroquinoline-3-carboxamide moiety.
    Tang Q; Zhai X; Tu Y; Wang P; Wang L; Wu C; Wang W; Xie H; Gong P; Zheng P
    Bioorg Med Chem Lett; 2016 Apr; 26(7):1794-8. PubMed ID: 26944614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3,4-dihydroquinoxaline moiety as c-Met kinase inhibitors.
    Liu J; Yang D; Yang X; Nie M; Wu G; Wang Z; Li W; Liu Y; Gong P
    Bioorg Med Chem; 2017 Aug; 25(16):4475-4486. PubMed ID: 28716639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.